The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients

Cancer Clinical Trial

— IPMR Balance  

Official title:

The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02391818
• Other study ID #: 599231-1
• Status: Completed
• Start date: February 2015
• Est. completion date: June 16, 2017

Study information

• Verified date: August 2019
• Source: OSF Healthcare System
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to quantify the balance impairments during and after taxane chemotherapy. Disability due to balance impairments caused by chemotherapy induced peripheral neuropathy (CIPN) can cause falls, injury, and a decline in independence. This results in poor treatment outcomes such as greater morbidity and mortality, inability to complete treatment protocols, self-limitation of activity, and diminished quality of life.

Description:

The purpose of this study is to describe the balance deficits prior to the initiation of taxane therapy and through the duration of treatment and compare balance to a cohort of women without taxane therapy. To our knowledge, a study like this has not been done yet it is a necessary next step in order to evaluate whether balance deficits resolve independent of treatment or if the balance deficits require targeted therapy. Other studies evaluating balance in taxane patients, have used cross-sectional study designs that are limited to observation at one point in time. Further, other evaluations have been limited in the measurement of balance using only self-report questionnaires, with no performance measurements of functional balance. Previous studies of other conditions have shown poor concordance between self-report questionnaires and performance measures. Therefore, our proposed longitudinal study improves the current knowledge about balance deficits during taxane therapy by quantifying the impact of taxane chemotherapy on balance during and after treatment using standardized and validated self-report and performance functional balance assessment tools. The results of this study will improve the treatment of balance deficits in women with taxane therapy by identifying the type, onset, duration, and severity of the deficits within each balance system. From these findings, targeted interventions, if required, could be developed. In addition, establishing feasibility and utility for quantifying balance impairments is necessary for the development of larger studies assessing the effects of rehabilitation interventions on functional disability due to CIPN. Such a study would be worthy of influencing changes in clinical practice to minimize disability from balance dysfunction before, during, and after chemotherapy, and thus maximizing function and quality of life during and after cancer treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: June 16, 2017
• Est. primary completion date: June 16, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Women with breast cancer (stage 0-III)

2. Scheduled to receive any of the following individual treatment protocols:

1. ACT

2. Radiation only

Exclusion Criteria:

1. Required assistive device for ambulation in the 6 months prior to starting treatment

2. Previous taxane or platinum chemotherapy (paclitaxel/Taxol®, docetaxel/Taxotere®, cabazitaxel/Jevtana®, cisplatin, carboplatin, and oxaliplatin)

3. Inability to stand or walk without assistance

4. BMI >40 (see chart below)

5. Pre-existing vestibular, visual, somatosensory, orthopedic, and neurologic disease before entering the study including but not limited to being legally blind (ICD9 368.3, 369.0-369.2 lower extremity amputation (ICD9 895.0-897.7), and Diabetes (ICD9 249.0-250.93, 257.2)

6. Evidence of central nervous system metastasis

7. Cognitive difficulties or medical conditions that, in the opinion of the study investigators, will affect testing protocols

8. Enrollment in other trial aimed at treating CIPN.

Related Conditions & MeSH terms

• Cancer
• Distorted; Balance
• Neuropathy
• Quality of Life

Locations

Country	Name	City	State
United States	Illinois CancerCare	Pekin	Illinois
United States	OSF Radiation Oncology	Pekin	Illinois
United States	Illinois CancerCare	Peoria	Illinois
United States	OSF Radiation Oncology	Peoria	Illinois

Sponsors (4)

Lead Sponsor	Collaborator
OSF Healthcare System	Illinois CancerCare, P.C., St. Francis Hospitals & Health Centers, University of Illinois College of Medicine at Peoria

Country where clinical trial is conducted

United States, 

References & Publications (9)

Dougherty BE, Flom RE, Bullimore MA. An evaluation of the Mars Letter Contrast Sensitivity Test. Optom Vis Sci. 2005 Nov;82(11):970-5. — View Citation

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb;33(1):15-49. Review. — View Citation

Lord SR, Menz HB. Visual contributions to postural stability in older adults. Gerontology. 2000 Nov-Dec;46(6):306-10. — View Citation

Mancini M, Horak FB. The relevance of clinical balance assessment tools to differentiate balance deficits. Eur J Phys Rehabil Med. 2010 Jun;46(2):239-48. Review. — View Citation

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009 Dec;17(12):1483-91. doi: 10.1007/s00520-009-0613-7. Epub 2009 Mar 28. — View Citation

Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012 Mar;20(3):583-9. doi: 10.1007/s00520-011-1127-7. Epub 2011 Mar 5. — View Citation

Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007 Aug;88(8):1002-8. — View Citation

Whitney SL, Wrisley DM, Marchetti GF, Gee MA, Redfern MS, Furman JM. Clinical measurement of sit-to-stand performance in people with balance disorders: validity of data for the Five-Times-Sit-to-Stand Test. Phys Ther. 2005 Oct;85(10):1034-45. — View Citation

Winters-Stone KM, Torgrimson B, Horak F, Eisner A, Nail L, Leo MC, Chui S, Luoh SW. Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil. 2011 Apr;92(4):646-52. doi: 10.1016/j.apmr.2010.10.039. Epub 2011 Mar 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline Modified Clinical Test of Sensory Integration of Balance at 9 months.	assessment of static balance under conditions eyes open on firm surface, eyes closed on firm surface, eyes open on foam surface, and eyes closed on foam surface	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Five Times Sit to STand	Time in seconds it takes to stand up and sit down from a standard height chair	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Visual Contrast Sensitivity	Using the Mars Letter Chart, a contrast sensitivity score is calculated	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Touch Detection Threshold	The lightest Von Frey Filament able to be detected using the up/down method is recorded on 3 places of each foot	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Patient Neurotoxicity Questionnaire	Likert scale describing the level of intensity of lower extremity neuropathy symptoms and their interference with functional activities	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Patient Neuropathy Function Questionnaire	number of falls are recorded, as well as Likert scales for various functional activities	An average of 5 months for the controls, and 9 months for the cases.
Secondary	Change from baseline Edmonton Symptom Assessment Scale	Quality of life scale validated for the breast cancer population	An average of 5 months for the controls, and 9 months for the cases.